NaviFUS
Taipei, Taiwan· Est.
A Taiwanese biotech leveraging non‑invasive focused ultrasound to breach the BBB for targeted CNS drug delivery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Taiwanese biotech leveraging non‑invasive focused ultrasound to breach the BBB for targeted CNS drug delivery.
OncologyNeurology
Technology Platform
Neuronavigation‑guided low‑frequency focused ultrasound that transiently opens the blood‑brain barrier and enables precise neuromodulation without invasive surgery.
Opportunities
Successful pivotal trials could unlock licensing deals with global pharma for BBB‑mediated drug delivery and expand the platform into other CNS indications.
Risk Factors
Regulatory complexity for combined device‑drug therapies, uncertain efficacy outcomes, and competition from alternative BBB‑opening technologies.
Competitive Landscape
Key competitors include Insightec (Exablate) and Carthera, but NaviFUS differentiates with a fully non‑invasive, neuronavigation‑guided approach that may lower procedural risk and cost.